Sophiris Bio, Inc. – OTC:SPHS
Sophiris Bio stock price today
Sophiris Bio stock price monthly change
Sophiris Bio stock price quarterly change
Sophiris Bio stock price yearly change
Sophiris Bio key metrics
Market Cap | N/A |
Enterprise value | 1.58M |
P/E | N/A |
EV/Sales | N/A |
EV/EBITDA | 2.16 |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | 0.27 |
Revenue | N/A |
EBITDA | 732K |
Income | 8.22M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeSophiris Bio stock price history
Sophiris Bio stock forecast
Sophiris Bio financial statements
| Dec 2018 | 0 | 14.13M | |
|---|---|---|---|
| Mar 2019 | 0 | -2.51M | |
| Jun 2019 | 0 | -2.31M | |
| Sep 2019 | 0 | -1.09M |
| Dec 2018 | 13199000 | 11.46M | 86.86% |
|---|---|---|---|
| Mar 2019 | 9612000 | 10.01M | 104.18% |
| Jun 2019 | 6441000 | 8.81M | 136.89% |
| Sep 2019 | 7099000 | 9.86M | 138.89% |
| Dec 2018 | -2.11M | 965K | 102K |
|---|---|---|---|
| Mar 2019 | -3.42M | 206K | -102K |
| Jun 2019 | -2.31M | 306K | -700K |
| Sep 2019 | -2.69M | -994K | 2.96M |
Sophiris Bio alternative data
| Aug 2023 | 6 |
|---|---|
| Sep 2023 | 6 |
| Oct 2023 | 6 |
| Nov 2023 | 6 |
| Dec 2023 | 6 |
| Jan 2024 | 6 |
| Feb 2024 | 6 |
| Mar 2024 | 6 |
| Apr 2024 | 6 |
| May 2024 | 6 |
| Jun 2024 | 6 |
| Jul 2024 | 6 |
Sophiris Bio other data
| Period | Buy | Sel |
|---|---|---|
| Sep 2018 | 10000 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | WOODS RANDALL E director, officer.. | Common Stock | 10,000 | N/A | N/A | ||
Sale | EKMAN LARS director | Common Stock | 9,663 | N/A | N/A | ||
Sale | BOXER CAPITAL, LLC 10 percent owner | Common Stock | 881,479 | N/A | N/A | ||
Purchase | WOODS RANDALL E director, officer.. | Common Stock | 3,000 | N/A | N/A | ||
Purchase | PROEHL GERALD T director | Common Stock | 10,000 | N/A | N/A | ||
Purchase | WOODS RANDALL E director, officer.. | Common Stock | 1,000 | N/A | N/A | ||
Purchase | WOODS RANDALL E director, officer.. | Common Stock | 1,000 | N/A | N/A | ||
Sale | HEPPELL JAMES L director | Common Stock | 19,231 | N/A | N/A | ||
Purchase | WOODS RANDALL E director, officer.. | Common Stock | 2,500 | N/A | N/A | ||
Purchase | SLOVER PETER T officer: Chief Financial Officer | Common Stock | 4,680 | N/A | N/A |
| Insider | Compensation |
|---|---|
| Mr. Randall E. Woods (1952) Pres, Chief Executive Officer & Director | $537,280 |
Friday, 20 December 2024 | ||
| Wisr AI Systems Inc. Announces Closing of Amalgamation | newsfilecorp.com |
-
What's the price of Sophiris Bio stock today?
One share of Sophiris Bio stock can currently be purchased for approximately $0.
-
When is Sophiris Bio's next earnings date?
Unfortunately, Sophiris Bio's (SPHS) next earnings date is currently unknown.
-
Does Sophiris Bio pay dividends?
No, Sophiris Bio does not pay dividends.
-
What is Sophiris Bio's stock symbol?
Sophiris Bio, Inc. is traded on the OTC under the ticker symbol "SPHS".
-
What is Sophiris Bio's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Sophiris Bio?
Shares of Sophiris Bio can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Sophiris Bio's key executives?
Sophiris Bio's management team includes the following people:
- Mr. Randall E. Woods Pres, Chief Executive Officer & Director(age: 73, pay: $537,280)
-
How many employees does Sophiris Bio have?
As Jul 2024, Sophiris Bio employs 6 workers.
-
When Sophiris Bio went public?
Sophiris Bio, Inc. is publicly traded company for more then 16 years since IPO on 18 Nov 2008.
-
What is Sophiris Bio's official website?
The official website for Sophiris Bio is sophirisbio.com.
-
Where are Sophiris Bio's headquarters?
Sophiris Bio is headquartered at 1258 Prospect Street, La Jolla, CA.
-
How can i contact Sophiris Bio?
Sophiris Bio's mailing address is 1258 Prospect Street, La Jolla, CA and company can be reached via phone at 858-777-1760.
Sophiris Bio company profile:
Sophiris Bio, Inc.
sophirisbio.comOTC
6
Biotechnology
Healthcare
Sophiris Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases. The company's primary product candidate is PRX302 (topsalysin), which is in Phase III clinical trial for treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer. It has a strategic relationship with Kissei Pharmaceutical Co., Ltd. for the development and commercialization of PRX302 for the treatment of the symptoms of BPH, prostate cancer, prostatitis, or other diseases of the prostate; and license agreement with UVIC Industry Partnerships Inc. and The Johns Hopkins University with respect to the use of PRX302 for the development of therapeutics for the symptoms of BPH, prostate cancer, and other non-cancer diseases and conditions of the prostate. The company was formerly known as Protox Therapeutics Inc. and changed its name to Sophiris Bio, Inc. in April 2012. Sophiris Bio, Inc. was founded in 2002 and is based in La Jolla, California.
La Jolla, CA 92037
CIK: 0001563855
ISIN: CA83578Q2099
CUSIP: 83578Q209
